MEDPLUS2023-10-012023-12-31 MEDPLUS2023-10-012023-12-31 MEDPLUS2023-10-012023-12-31in-bse-fin:OneOperatingExpenses01Member MEDPLUS2023-10-012023-12-31in-bse-fin:FourOperatingExpenses01Member MEDPLUS2023-12-31 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 543427 MEDPLUS NOTLISTED Medplus Health Services Limited Equity 2023-04-01 2024-03-31 2024-02-02 2023-12-27 INR Millions Third quarter 14:30:00 16:45:00 2024-02-02 2024-02-02 Not applicable Single segment In accordance with Ind AS 108, Operating Segments, segment information has been given in the consolidated financial statements of MedPlus Health Services Private Limited and therefore no separate disclosure on segment information is given in these standalone financial statements 2023-10-01 2023-12-31 Unaudited Standalone 1480970000.00 18230000.00 1499200000.00 125370000.00 1015710000.00 10060000.00 112920000.00 21040000.00 62660000.00 109020000.00 1456780000.00 42420000.00 0.00 42420000.00 10540000.00 0.00 10540000.00 0.00 31880000.00 0.00 0.00 0.00 0.00 31880000.00 3660000.00 35540000.00 0.00 0.00 239070000.00 2 0.27 0.27 0.00 0.00 0.27 0.27 Notes to the Unaudited standalone financial results: 1. The above unaudited standalone financial results of MedPlus Health Services Limited ('The Company') have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“listing regulations”) from time to time. These unaudited standalone financial results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meetings held on February 02, 2024. These financial results have been subjected to limited review by the Statutory Auditors of the Company and the auditors have expressed and issued an unqualified review report on the same. 2. During the year ended March 31, 2022, the Company has completed its Initial Public Offering (IPO) of 17,573,342 equity shares of face value of Rs. 2 each for cash at an issue price of Rs. 796 per equity share aggregating to Rs. 13,982.95 million, consisting of Fresh Issue of 7,544,511 equity shares amounting to Rs. 6,000 million and an offer for sale of 10,028,831 equity shares amounting to Rs. 7,982.95 million by the Selling Shareholders. Pursuant to the IPO, the equity shares of the Company were listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) with effect from 23 December 2021. The utilization of IPO proceeds received by the Company (net of IPO related expense) is summarized below: (Rs. In Millions) Objects as per Prospectus Planned utilisation as per Prospectus Utilisation up to December 31, 2023 Unutilised amount as on December 31, 2023* i) Investment in Subsidiary - Optival Health Solutions Private Limited towards their working capital requirements 4,671.70 4,671.70 - ii) General Corporate Purposes 1,111.03 448.53 662.50 Total 5,782.73 5,120.23 662.50 * The aforesaid unutilised proceeds of Rs. 662.50 million have been placed as fixed deposits with bank. 3. As per Ind AS 108 'Operating segments', the Company has disclosed the segment information only as part of the consolidated financial results. 4. The Board of Directors of the Company, at their meeting held on January 10, 2023, have approved a Scheme of amalgamation (Scheme) between the Company and MHS Pharmaceuticals Private Limited (MHS), a wholly owned subsidiary, with an appointed date of April 01, 2023. During the quarter, the Company has received approval from equity shareholders and trade creditors at their meeting held on December 15, 2023, pursuant to NCLT order dated November 07, 2023. The management has filed the final petition for approval under section 232 read with section 230 of the Companies Act, 2013 dated December 26, 2023. 5. During the year ended 31 March 2023, the Company recognised provision for impairment of its investments and loans receivable (including interest) from Kalyani Meditimes Private Limited, a Subsidiary, to the tune of Rs.56.33 million. The Company, during the said period, has also reversed impairment provision made during the prior periods to the tune of Rs.125.77 million in respect of investments in another subsidiary, WynClark Pharmaceuticals Private Limited. These amounts were recorded/reversed pursuant to management assessment of the future cash flows of the underlying subsidiary Companies and their historic and projected profitability. 6. The above financial results are also available at the Stock Exchange's website i.e. www.bseindia.com, www.nseindia.com and the Company's website www.medplusindia.com. For and on behalf of the Board of Directors of MedPlus Health Services Limited Single segment 2023-04-01 2023-12-31 Unaudited Standalone 3186620000.00 53950000.00 3240570000.00 325560000.00 2063260000.00 -2570000.00 319310000.00 62930000.00 177680000.00 287210000.00 3233380000.00 7190000.00 0.00 7190000.00 10540000.00 0.00 10540000.00 0.00 -3350000.00 0.00 0.00 0.00 0.00 -3350000.00 9500000.00 6150000.00 0.00 0.00 239070000.00 2 -0.03 -0.03 0.00 0.00 -0.03 -0.03 Other expenses 109020000.00 Other expenses 287210000.00 3660000.00 9500000.00 0.00 0.00 0.00 0.00